Feature | March 19, 2012

‘Heartless’ Politician Re-Elected, Performs Duties of Office With Artificial Heart

On Nov. 8, 2011, SynCardia Total Artificial Heart patient Jack Miller became the first politician in the United States to be elected to office without a human heart. On election day, he was able to man the polls and interact with voters using the Freedom portable driver to power his Total Artificial Heart.

SynCardia Total Artificial Heart patient Jack Miller was able to enjoy Christmas

SynCardia Total Artificial Heart patient Jack Miller was able to enjoy Christmas at home last month with his wife Mary Lou and their grandchildren, 8-year-old Emma and 5-year-old Matthew, while waiting for a matching donor heart.

Jack Miller, 62, is probably the only politician in America who smiles when people call him “heartless.” Four months ago, doctors at Virginia Commonwealth University (VCU) Medical Center in Richmond removed his dying heart and replaced it with the SynCardia temporary Total Artificial Heart.

"Golly day, I feel so much better," Miller said, who received his Total Artificial Heart on Sept. 15, 2011. "It's like my body is reawakening for the first time in 11 years. I'm just amazed. No one will ever know how appreciative I am to be able to wait for my heart transplant at home in my community with my family.”

Less than a month after receiving the SynCardia product, Miller was discharged from the hospital using the Freedom portable driver to power his Total Artificial Heart. That same day, he and his wife Mary Lou celebrated their 44th wedding anniversary.

“He is the only boy I ever dated in high school, and I married him soon after we got out of school, and he is my life,” Mary Lou said. “I told one of the nurses one day, if something were to happen to him, you would lose a patient. But if something happens to him, for me, I lose everything.”

On Nov. 1, 2011, Miller was able to return to his position as chairman of the Middlesex County Board of Supervisors and conduct his first meeting with his Total Artificial Heart. Just a week later, Miller was up for re-election.

“I manned the polls on election day and interacted with the voters I represent,” Miller said, who was successfully re-elected to his fifth term in office. “We plugged the Freedom driver into my car’s cigarette lighter and it worked fine. During this whole process, my Freedom driver allowed me to accomplish my goals. It let the citizens know I was up and active and could continue to serve them.”

Miller was first diagnosed with dilated cardiomyopathy 11 years ago. Over the years, his heart continued to weaken, and eventually he was implanted with a defibrillator to shock his heart back into rhythm when it became erratic. After a bad episode of shocks from the defibrillator in September 2011, Mr. Miller’s heart was barely functioning. To save his life, doctors implanted the Total Artificial Heart to bridge him to a heart transplant.

The Freedom driver is CE-approved for use in Europe and undergoing a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study in the United States. Weighing 13.5 pounds, the Freedom driver is the world’s first wearable power supply for SynCardia’s Total Artificial Heart. It is an investigational device, limited by United States law to investigational use.

SynCardia Systems Inc. is the manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia’s Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

For more information: www.syncardia.com

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Overlay Init